Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space
Data at ASCO showed a statistically significant overall survival advantage in pre- and perimenopausal women with advanced HR+, HER2- breast cancer, a first for the CDK4/6 class.
Data at ASCO showed a statistically significant overall survival advantage in pre- and perimenopausal women with advanced HR+, HER2- breast cancer, a first for the CDK4/6 class.